Two Sigma Securities, LLC Fibrogen Inc Transaction History

Two Sigma Securities, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.89 - $2.36 $3,106 - $8,236	3,490 Added 25.19%	17,342 $15,000
Q1 2024 May 15, 2024	SELL	$0.73 - $2.73 $1,454 - $5,438	-1,992 Reduced 12.57%	13,852 $32,000
Q4 2023 Feb 14, 2024	BUY	$0.38 - $0.91 $194 - $466	513 Added 3.35%	15,844 $14,000
Q3 2023 Nov 14, 2023	SELL	$0.79 - $2.83 $722 - $2,589	-915 Reduced 5.63%	15,331 $13,000
Q2 2023 Aug 14, 2023	BUY	$2.49 - $20.59 $40,452 - $334,505	16,246 New	16,246 $43,000
Q1 2020 May 15, 2020	SELL	$23.3 - $45.96 $121,369 - $239,405	-5,209 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$34.58 - $48.06 $180,127 - $250,344	5,209 New	5,209 $223,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Two Sigma Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Securities, LLC with notifications on news.